Press releases
- Dexcom Publishes Annual Sustainability Report
- Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
- Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
- Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
- Dexcom Announces Upcoming Conference Presentation
- Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- Dexcom Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People
- Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time
More ▼
Key statistics
As of last trade Dexcom Inc (DXCM*:MEX) traded at 2,260.00, -2.54% below its 52-week high of 2,318.97, set on Jul 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | 2,200.01 |
Offer | 2,309.99 |
Previous close | 2,260.00 |
Average volume | -- |
---|---|
Shares outstanding | 385.52m |
Free float | 383.97m |
P/E (TTM) | 104.76 |
Market cap | 51.77bn USD |
EPS (TTM) | 1.28 USD |
Data delayed at least 20 minutes, as of Apr 04 2024 18:29 BST.
More ▼